BioSpace News Archive

Avanos Medical, Inc. (NYSE: AVNS) today announced that Joe Woody, chief executive officer, will present at the 39th Annual J.P. Morgan Healthcare Conference via webcast on Wednesday Jan. 13 at approximately 2 p.m. ET.

Health Net Federal Services, LLC, a wholly owned subsidiary of Centene Corporation, announced it has earned URAC accreditations in Health Utilization Management, Case Management and Disease Management.

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or “the Company”), a specialty biopharmaceutical company, today announced that RHB-204 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for its development as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex

Blair C. Jackson Appointed Chief Operating Officer and Iain M. Brown Named Chief Financial Officer, Positioning Company for Continued Strong Execution of Business Strategy

Pharmacy Benefit Manager Receives $100 Million Capital Commitment to Expand Unique Model Delivering Significant Savings to U.S. Employers

Axial Therapeutics Inc., a clinical-stage biotechnology company dedicated to building a unique class of gut-restricted therapeutics for central nervous system (CNS) disorders and conditions, today announced that management will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference 2021.

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14 at 11:40 a.m. ET.

Appili Therapeutics Inc. (TSX: APLI, OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, announced today that Appili’s CEO Dr. Armand Balboni will participate in HC Wainwright’s Bioconnect 2021 investor event. The virtual conference takes place from January 11 – 14, 2021. Presentation details are as follows: Type: Pre-recorded Company Pre

AstraZeneca’s FARXIGA (dapagliflozin) has been granted Priority Review in the US for the treatment of new or worsening chronic kidney disease (CKD) in adults with and without type 2 diabetes (T2D).

Expanded primary care network makes it easier for Medicare Advantage patients to access enhanced primary care designed specifically for them